EH301 for the Treatment of ALS

Amyotrophic Lateral Sclerosis Clinical Trial

Official title:

EH301 for the Treatment of Amyotrophic Lateral Sclerosis: a Placebo-Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03489200
• Other study ID #: H1479983999044
• Status: Completed
• Phase: N/A
• Start date: January 2017
• Est. completion date: June 2017

Study information

• Verified date: May 2018
• Source: Elysium Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this trial is to evaluate the efficacy and tolerability of EH301 in patients with amyotrophic lateral sclerosis. Patients with ALS are randomized to receive either EH301 or placebo daily and undergo active evaluation for 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years or older

• Diagnosis of probable or definite (sporadic or familial) ALS by El Escorial criteria

• Onset of symptomatology for more than 6 months

• If female: not lactating; negative pregnancy test; agree to use an effective method of birth control throughout study

Exclusion Criteria:

• Tracheostomy, invasive ventilation, or non-invasive positive pressure ventilation

• Gastrostomy

• Evidence of major psychiatric disorder or clinically evident dementia

• Diagnosis of a neurodegenerative disease in addition to ALS

• Current medication apart from riluzole that in the opinion of the investigator would make the patient unsuitable for study participation

• Recent history (within the previous 6 months) or current evidence of alcohol or drug abuse

• Concurrent unstable disease involving any system (e.g. carcinoma other than basal cell carcinoma), any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of coronary artery disease, or any other condition that in the opinion of the investigator would make the patient unsuitable for study participation

• Baseline QTc (Bazett) > 450 msec for males and > 470 msec for females

• Known hepatitis B/C or HIV positive serology

• Renal impairment defined as blood creatinine > 2x ULN

• Hepatic impairment and/or liver enzymes (ALT or AST) > 3x ULN

• Hemostasis disorders or current treatment with oral anticoagulants

• Participated in any other investigational drug or therapy study with a non-approved medication, within the previous 3 months

• No medical insurance

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Other:
• EH301
1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene
• Placebo
No intervention- placebo

Locations

Country	Name	City	State
Spain	Universidad Católica de Valencia San Vicente Màrtir	Valencia

Sponsors (3)

Lead Sponsor	Collaborator
Elysium Health	Fundación Universidad Católica de Valencia San Vicente Mártir, University of Valencia

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ALSFRS-r	ALS Functional Rating Scale - revised score is a summation of ratings across across fine and gross motor, bulbar and respiratory functional domains. The scale ranges from 0-48, with higher total score representing better outcomes. The twelve subscales are rated on a five-point scale from 0 (can't do) to 4 (normal ability) and combined to compute the total score. This outcome measures change observed from baseline to 6 months.	6 months
Secondary	MRC	Medical Research Council Scale measures the strength of muscles in ALS patients. This 11-step grading scale is a summation of scores for 8 different muscles, each with a subscale of 0 (no muscle contraction) to 5 (normal power). To calculate the total MRC Index a progressively increasing number from 0 (0 in the scale) to 10 (5 in the scale) is given to each step and each muscle. The total MRC index per patient corresponds to the sum of the numbers given to all 8 muscles. This outcome measures change observed in MRC Index from baseline to 6 months.	6 months
Secondary	FVC	Forced Vital Capacity is a predictor of survival and disease progression in ALS patients and is measured using a touch spirometer and expressed as the % of standard value depending on sex, weight, and age parameters. This outcome measures change observed from baseline to 6 months.	6 months
Secondary	Electromyogram	A surface electromyogram (EMG) measuring device is used to measure muscle activity in the same muscles as the MRC Index. Muscle activity is expressed as the EMG amplitude (uV).; This outcome measures change in EMG amplitude observed from baseline to 6 months.	6 months
Secondary	Anthropometry	Fat and skeletal muscle weights (kg) are calculated following standard anthropometric procedures. Fat and skeletal weight outcomes refer to change observed comparing baseline vs 6 months.	6 months